If you have been reading about Cardarine and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-04. Numbers and descriptions here follow the published literature rather than marketing material.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
The increasing amount of genomic and molecular information is the basis for understanding higher-order biological systems, such as the cell and the organism, and their interactions with the environment, as well as for medical, industrial and other practical applications. The KEGG resource provides a reference knowledge base for linking genomes to biological systems, categorized as building blocks in the genomic space (KEGG GENES), the chemical space (KEGG LIGAND), wiring diagrams of interaction networks and reaction networks (KEGG PATHWAY), and ontologies for pathway reconstruction (BRITE database). The KEGG PATHWAY database is a collection of manually drawn pathway maps for metabolism, genetic information processing, environmental information processing such as signal transduction, ligand–receptor interaction and cell communication, various other cellular processes and human diseases, all based on extensive survey of published literature.
If the predicted half-life falls into an experimentally accessible range, such isotopes have a chance to move from the list of stable nuclides to the radioactive category, once their activity is observed. For example, 209Bi and 180W were formerly classed as stable, but were found to be alpha-active in 2003. However, such nuclides do not change their status as primordial when they are found to be radioactive. Most stable isotopes on Earth are believed to have been formed in processes of nucleosynthesis, either in the Big Bang, or in generations of stars that preceded the formation of the Solar System. However, some stable isotopes also show abundance variations in the earth as a result of decay from long-lived radioactive nuclides. These decay-products are termed radiogenic isotopes, in order to distinguish them from the much larger group of 'non-radiogenic' isotopes.
Tens of genes and CNVs have been definitively identified based on the observation of recurrent mutations in different individuals, and suggestive evidence has been found for over 100 others. The Simons Foundation Autism Research Initiative (SFARI) details the evidence for each genetic locus associated with autism. These early gene and CNV findings have shown that the cognitive and behavioral features associated with each of the underlying mutations is variable. Each mutation is itself associated with a variety of clinical diagnoses, and can also be found in a small percentage of individuals with no clinical diagnosis. Thus the genetic disorders that comprise autism are not autism-specific. The mutations themselves are characterized by considerable variability in clinical outcome and typically only a subset of mutation carriers meet criteria for autism. This variable expressivity results in different individuals with the same mutation varying considerably in the severity of their observed particular trait. The conclusion of these recent studies of de novo mutation is that the spectrum of autism is breaking up into quanta of individual disorders defined by genetics. One gene that has been linked to autism is SHANK2. Mutations in this gene act in a dominant fashion and appear to cause hyperconnectivity between the neurons. A study conducted on 42,607 autism cases has identified 60 new genes, five of which had a more moderate impact on autistic symptoms. The related gene variants were often inherited from the participant's parents.
== History == The War Office developed from the Council of War, an ad hoc grouping of the King and his senior military commanders which managed the Kingdom of England's wars and campaigns. The management of the War Office was directed initially by the Secretary at War, whose role had originated during the reign of King Charles II as the secretary to the Commander-in-Chief of the Army. In the latter part of the 17th century, the office of Commander-in-Chief was vacant for several periods, which left the Secretary at War answering directly to the Sovereign; and thereafter, even when the office of Commander-in-Chief was restored on a more permanent basis, the Secretary at War retained his independence. The department of the Secretary at War was referred to as the 'Warr Office' (sic) from as early as 1694; its foundation has traditionally been ascribed to William Blathwayt, who had accompanied King William III during the Nine Years' War and who, from his appointment as Secretary in 1684, had greatly expanded the remit of his office to cover general day-to-day administration of the Army. After Blathwayt's retirement in 1704, Secretary at War became a political office. In political terms, it was a fairly minor government job (despite retaining a continued right of access to the monarch) which dealt with the minutiae of administration, rather than grand strategy. The Secretary, who was usually a member of the House of Commons, routinely presented the House with the Army Estimates, and occasionally spoke on other military matters as required.
==== TPN-based cholestasis ==== Total parenteral nutrition (TPN) is given to patients with intestinal failure or a variety of other gastrointestinal problems. Under normal settings, TPN causes a slight elevation of ALP levels. However, this does not indicate cholestasis alone. In the case of TPN-induced cholestasis, there is an excessive elevation of ALP, gamma-glutamyltransferase (GGT), and conjugated bilirubin. Without appropriate intervention, symptoms can quickly exacerbate, leading to liver cirrhosis and failure. Cholestasis arising from TPN has a diverse range of causes, including toxicity to TPN components, underlying disorders, or a lack of enteral nutrition. Without enteral food consumption, gallbladder function is greatly inhibited, leading to gallstone formation, subsequent blockage, and eventually cholestasis. Cholestasis resulting from TPN may also be a result of reduced bile flow from portal endotoxins. With TPN, there is a reduction in gastrointestinal motility, immunity, with an increase in permeability. These changes facilitate bacteria growth and increase the amount of circulating endotoxin. Moreover, given that patients using TPN often have underlying health problems, drugs being used with known liver toxicity may also cause cholestasis. Lipids in TPN may cause cholestasis and liver damage by overwhelming clearage mechanisms. Intravenous glucose can also cause cholestasis as a result of increased fatty acid synthesis and decreased breakdown, which facilitates the accumulation of fats.
Sources: en.wikipedia.org
Adorno, Theodor. Aesthetic Theory. Archived 8 July 2011 at the Wayback Machine University of Minnesota Press, 1996 Fieser, James; Dowden, Bradley (eds.). "Theodor Adorno". Internet Encyclopedia of Philosophy. ISSN 2161-0002. OCLC 37741658. Zuidervaart, Lambert. "Theodor W. Adorno". In Zalta, Edward N. (ed.). Stanford Encyclopedia of Philosophy. ISSN 1095-5054. OCLC 429049174. Illuminations – The Critical Theory Project Odysseus and the Siren Call of Reason: The Frankfurt School Critique of Enlightenment published in Other Voices, n.1 v.1, 1997. "Adorno during the 1950s" by Juergen Habermas Archived 7 February 2016 at the Wayback Machine Daniel Sherer, "Adorno's Reception of Loos: Modern Architecture, Aesthetic Theory, and the Critique of Ornament", Potlatch 3 (Spring 2014), 19–31. Sound recordings with Theodor W. Adorno in the Online Archive of the Österreichische Mediathek (Scientific lectures) (in German) Theodor W. Adorno discography at Discogs Review of Prisms (1955) The Boston Phoenix (1982)
Acupuncture is a substantial part of traditional Chinese medicine (TCM). Early acupuncture beliefs relied on concepts that are common in TCM, such as a life force energy called qi. Qi was believed to flow from the body's primary organs (zang-fu organs) to the "superficial" body tissues of the skin, muscles, tendons, bones, and joints, through channels called meridians. Acupuncture points where needles are inserted are mainly (but not always) found at locations along the meridians. Acupuncture points not found along a meridian are called extraordinary points and those with no designated site are called A-shi points. In TCM, disease is generally perceived as a disharmony or imbalance in energies such as yin, yang, qi, xuĕ, zàng-fǔ, meridians, and of the interaction between the body and the environment. Therapy is based on which "pattern of disharmony" can be identified. For example, some diseases are believed to be caused by meridians being invaded with an excess of wind, cold, and damp. In order to determine which pattern is at hand, practitioners examine things like the color and shape of the tongue, the relative strength of pulse-points, the smell of the breath, the quality of breathing, or the sound of the voice. TCM and its concept of disease does not strongly differentiate between the cause and effect of symptoms. Acupuncture was and is practiced differently by various Chinese philosophical schools, and differs from acupuncture from Korea and Japan.
== Discovery and sequencing == The gene encoding myostatin was discovered in 1997 by geneticists Se-Jin Lee and Alexandra McPherron who produced a knockout strain of mice that lack the gene, and have approximately twice as much muscle as normal mice. These mice were subsequently named "mighty mice". Naturally occurring deficiencies of myostatin of various sorts have been identified in some breeds of cattle, sheep, whippets, and humans. In each case the result is a dramatic increase in muscle mass.
Lateral meristem: Cells which mainly divide in one plane and cause the organ to increase in diameter and girth. Lateral meristem usually occurs beneath the bark of the tree as cork cambium and in vascular bundles of dicotyledons as vascular cambium. The activity of this cambium forms secondary growth. Intercalary meristem: Located between permanent tissues, it is usually present at the base of the node, internode, and on leaf base. They are responsible for growth in length of the plant and increasing the size of the internode. They result in branch formation and growth. } This part is a bit misleading. Somebody wanna fix? The cells of meristematic tissue are similar in structure and have a thin and elastic primary cell wall made of cellulose. They are compactly arranged without intercellular spaces between them. Each cell contains a dense cytoplasm and a prominent cell nucleus. The dense protoplasm of meristematic cells contains very few vacuoles. Normally the meristematic cells are oval, polygonal, or rectangular in shape. Meristematic tissue cells have a large nucleus with small or no vacuoles because they have no need to store anything. Their basic function is to multiply and increase the girth and length of the plant, with no intercellular spaces.
=== Europe === As of 2011, the plant was controlled in Denmark, Latvia, Lithuania, Poland, Romania, and Sweden. In Bulgaria and Norway, kratom is a controlled substance. In the Czech Republic, regulated sales of kratom and kratom extracts became legal starting in July 2025. In Finland, scheduled in the "government decree on psychoactive substances banned from the consumer market". In the Republic of Ireland in 2017, kratom was designated a Schedule 1 illegal drug (the highest level), under the names 7-hydroxymitragynine and mitragynine. In the UK, the sale, import, and export of kratom is prohibited under the Psychoactive Substances Act 2016, which broadly bans any substance that "produces a psychoactive effect".
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.